Sheffield Medical Technologies Inc. has received rights to co-developand market therapeutic compounds discovered by researchers atHarvard University for treatment of skin diseases, such as Kaposi'ssarcoma and psoriasis.Sheffield's Gloria Mechaley said financial terms were not disclosed.The deal also involves a one-year research agreement with Harvard anda collaboration with Pharm-Eco Laboratories Inc., of Lexington, Mass.,to develop drugs that may evolve from the studies.Houston-based Sheffield said the compounds under development byHarvard researchers are active through modulation of ion transport.Physician-sponsored trials are being conducted for topicaladministration of the drugs and those studies will be used to supportinvestigational new drug applications with the FDA.The company said treatment of Kaposi's sarcoma likely would be thefirst target of clinical trials followed by studies for other dermatologicalconditions, such as psoriasis, displastic nevi, basal cell carcinoma andother proliferative disorders. _ Charles Craig

(c) 1997 American Health Consultants. All rights reserved.

No Comments